NA
IOBT

NewEdge Advisors’s IO Biotech IOBT Stock Holding History

NewEdge Advisors’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,692
Closed -$9.33K – 4309
2025
Q3 		$9.33K Buy
25,692
+1,475
+6% +$2.54K ﹤0.01% 3346
2025
Q2 		$33.7K Buy
+24,217
New +$27.7K ﹤0.01% 2783

Other funds holding IOBT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

NewEdge Advisors's IOBT Position: Q4 2025 in Review

NewEdge Advisors sold out of IO Biotech (IOBT) in Q4 2025, closing a stake of 25,692 shares — an estimated $9.33K sold.

NewEdge Advisors first reported a position in IOBT in Q2 2025 and held it in 2 quarters. The position peaked at $33.7K in Q2 2025. 22 funds tracked by Wall St. Rank hold IOBT as of Q4 2025.

  • NewEdge Advisors reported no remaining IO Biotech position as of Q4 2025 after selling out during the quarter.
  • NewEdge Advisors sold 25,692 IO Biotech shares in Q4 2025, an estimated $9.33K.
  • NewEdge Advisors first reported a position in IO Biotech in Q2 2025 and held it in 2 quarters.
  • NewEdge Advisors's IO Biotech position peaked at $33.7K in Q2 2025.
  • 22 funds tracked by Wall St. Rank held IO Biotech as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.